{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:50:32Z","timestamp":1779313832096,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jacc.2022.10.033","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T19:02:34Z","timestamp":1674500554000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparative Risk of Angioedema With\u00a0Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone\u00a0Inhibitors"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8971-9748","authenticated-orcid":false,"given":"Efe","family":"Eworuke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily C.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Haug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casie","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacc.2022.10.033_bib3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jacc.2022.10.033_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacc.2022.10.033_bib5","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2022.10.033_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"issue":"suppl 1","key":"10.1016\/j.jacc.2022.10.033_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/pds.2336","article-title":"Design considerations, architecture, and use of the Mini-Sentinel distributed data system","volume":"21","author":"Curtis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.jacc.2022.10.033_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pds.2319","article-title":"A\u00a0policy framework for public health uses of electronic health data","volume":"21","author":"McGraw","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.jacc.2022.10.033_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/pds.2242","article-title":"The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program","volume":"21","author":"Forrow","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jacc.2022.10.033_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jacc.2022.10.033_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jama.1997.03550030072037","article-title":"Recurrent angiotensin-converting enzyme inhibitor--associated angioedema","volume":"278","author":"Brown","year":"1997","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacc.2022.10.033_bib13","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.jacc.2022.10.033_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A\u00a0combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"20","key":"10.1016\/j.jacc.2022.10.033_bib15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.jacc.2022.10.033_bib16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pds.4260","article-title":"Antihypertensive drug associated angioedema: effect modification by race\/ethnicity","volume":"26","author":"Reichman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"10.1016\/j.jacc.2022.10.033_bib17","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jacc.2022.10.033_bib18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/aje\/kwp173","article-title":"Influenza vaccination and mortality: differentiating vaccine effects from bias","volume":"170","author":"Fireman","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.jacc.2022.10.033_bib19","first-page":"29","article-title":"Evaluation of the US Food and Drug Administration Sentinel Analysis Tools using a comparator with a different indication: comparing the rates of gastrointestinal bleeding in warfarin and statin users","volume":"33","author":"Carnahan","year":"2019","journal-title":"Pharmaceut Med"},{"issue":"7","key":"10.1016\/j.jacc.2022.10.033_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pds.4420","article-title":"Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: the case of clindamycin and Clostridium difficile infection","volume":"27","author":"Carnahan","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.jacc.2022.10.033_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cpt.429","article-title":"Successful comparison of US Food and Drug Administration Sentinel Analysis Tools to traditional approaches in quantifying a known drug-adverse event association","volume":"100","author":"Gagne","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jacc.2022.10.033_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"issue":"7-8","key":"10.1016\/j.jacc.2022.10.033_bib25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1345\/aph.1C520","article-title":"Valsartan-induced angioedema","volume":"37","author":"Irons","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.jacc.2022.10.033_bib26","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e3181f28f84","article-title":"Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review","volume":"19","author":"Kalra","year":"2012","journal-title":"Am J Ther"},{"issue":"3","key":"10.1016\/j.jacc.2022.10.033_bib27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaip.2017.03.017","article-title":"Cardiovascular and diabetic medications that cause bradykinin-mediated angioedema","volume":"5","author":"Hudey","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jacc.2022.10.033_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10557-021-07157-3","article-title":"A\u00a0pharmacovigilance study of adverse drug reactions reported for cardiovascular disease medications approved between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database","volume":"36","author":"Patel","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"10.1016\/j.jacc.2022.10.033_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/pds.4550","article-title":"Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies\u2014an application to the known association between angiotensin-converting enzyme inhibitors and angioedema","volume":"27","author":"Panozzo","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722074241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722074241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T12:53:26Z","timestamp":1732884806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722074241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0735109722074241"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2022.10.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Risk of Angioedema With\u00a0Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone\u00a0Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2022.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}